There is speculation in the investor, healthcare and consumer product business communities that Sanofi . | Erfahren Sie mehr . <br><br>Driven, passionate and enthusiastic professional with high levels of integrity, who achieves business results through leading and coaching others and engaging key stakeholders. Sanofi assumes no responsibility for the information presented on this website. All in all, even though the stagnant divisions are at the moment predominant, that story is changing. As a result, French Tech Souverainet will become a long-term reference shareholder of EUROAPI and will be represented by two non-executive members on EUROAPI's Board of Directors, including Benjamin Paternot and another member to be determined. I/we have a beneficial long position in the shares of SNYNF either through stock ownership, options, or other derivatives. Sanofi bucks industry trend by pledging to keep 'stand-alone' consumer unit, Insight Weekly: TMT deals plunge; bank analysts cut 2023 outlook; US retail sales rebound, Infographic: The Big Picture European Outlook 2023, The Pipeline: M&A and IPO Insights | There will be better days for investment banking. Post transaction, Sanofi confirms that it will hold circa 30% of the share capital and voting rights of EUROAPI and will remain a long-term strategic partner, supporting EUROAPIs growth ambitions as an independent company over the coming years. McGarry cited the potential for this spinoff, combined with a spinout of Sanofi's pharmaceutical ingredients business that Hudson said is expected "in just a few months," as reasons for upgrading stock in the Paris-based drugmaker to a "buy.". The Board of Sanofi (ENXTPA:SAN) completed the spin-off 58% stake in EuroAPI on May 6, 2022. R&D Spend: USD 13.080 billion. Further details regarding the specifics of the distribution, including the parity, and the timetable of the spin-off will be set forth in EUROAPIs French prospectus. Executive Vice President, Consumer Healthcare, on International Self-Care Day 2021. If you wish to continue to this external website, click Proceed. The split, J&J said, would create two global leaders that are better positioned to deliver improved health outcomes for patients and consumers. Sanofi (XPAR:SAN) Dividend Payout Ratio as of today (March 01, 2023) is 0.00. Dividend Payout Ratio explanation, calculation, historical data and more Please contact the Global Headquarters in France . "If the GlaxoSmithKline Consumer Health spinoff goes well, we believe it is likely that Sanofi could spin off its consumer health business as well, which is a reasonable extension of the internal separation that is ongoing," HSBC analyst Steve McGarry said in a Nov. 1 note. Moreover, the deal was in line with GSKs plan to demerge the JV from the company and to list the GSK Consumer Healthcare business on the UK equity market. 2021 position: 10. The company's consumer healthcare unit, a maker of over-the-counter drugs (OTC), lifted sales by 9.1% to 1.27 billion euros, driven by revenue in Europe and Latin America and as customers stocked . The joint venture was then spun off and listed separately. Patents; Patient Support Services; Resources for Healthcare Providers; Colorado Disclosure; Vermont Disclosure; Our Responsibility. Additionally, the oncology division is experiencing a strong momentum, with Sarclisa and Libtayo bringing a 25% growth rate. Through this transaction, Sanofi is giving its shareholders the opportunity to take part in the success of a leading player in the API market with strong ambitions to become a global champion on a growing and dynamic market, and due to be listed on the regulated market of Euronext Paris. By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Scotland Health Tech privacy policy. They are the essential molecules used in the composition and manufacture of any medicine. Sanofi is offering its animal health unit Merial in exchange for Boehringer's consumer health, or non-prescription drugs, business plus 4.7 billion euros ($5.2 billion) in cash in exclusive . Business is on track to demerge and list as a new company in mid-2022. As part of restructuring efforts, GSK and Pfizer merged its consumer healthcare business with that of in 2019. I have developed a broad set . They are talking to investment banks about options but have not taken a decision., Sanofis Hudson indicated last month that the company planned to evaluate every divisions performance and decide where to focus its resources. Culture and talent. Home . The net debt/adjusted EBITDA leverage ratio is expected be less than 2x. -. 1 Companys estimate based on third-party market research conducted using the annual reports published by the main industrial players in the APIs sector, public databases (including Capital IQ and Orbis) as well as interviews with market experts. It planned to form a new Primary Care global business unit that would combine the product portfolios from its existing Diabetes and Cardiovascular (DCV) unit with Established Products. Morningstar analyst Damien Conover said: The firms timing is surprising, as we dont see any major catalyst for the move. We leverage the best in science, together with our world-class pharmaceutical quality standards, to deliver consumer-driven, innovative medicines and products for allergy; pain; digestive wellness; cough, cold and flu; and physical and mental wellness. Get Your 7-Day Free Trial! The company has also claimed that some of its major shareholders support the spin-off deal. Employing over 100,000 workers, it generates over $42 billion in annual sales and is ranked at #288 in the Fortune 500. It followed a historic slump in over-the-counter sales for cough and cold medicines across the industry in 2020 as a result of social distancing and other pandemic-related regulations. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in Sanofis annual report on Form 20-F for the year ended December 31, 2021. Rx Sales: USD 49.293 billion. Paul Hudson, Sanofis chief executive officer, who took over the reins of the company on September 1, is expected to meet with investors in Cambridge, Massachusetts on December 10. Global markets live: GM, Pfizer, Exxon, UBS, Boeing EUROAPI Announces Resignation of Corinne Le Goff as an Independent Member on the Board .. I wrote this article myself, and it expresses my own opinions. Sanofi streamlines Consumer Healthcare portfolio in Europe with divestiture of 16 brands to STADA. Media Relations Notice The company focuses on a three-pillar strategy consisting of generics, specialty pharma and non-prescription consumer healthcare products. In addition to the previously proposed 3.33 cash dividend per Sanofi share, this additional extraordinary dividend, exclusively in kind, is subject to shareholders approval at Sanofi's May 3, 2022 Ordinary and Extraordinary Shareholders' Meeting. The company expects a strong drug pipeline, backed by strong research and development expenses to drive sustainable, long-term growth for the pharmaceutical business. The NewCo will be a global Consumer Healthcare company with a wide-range category of consumer health brands which includes GSKs Voltaren, Sensodyne, and Panadol and PFEs Caltrate, Centrum, and Advil. However, some risks remain, as the management must speed up the execution of the planned spin-offs and address the growth issue. There is even a name for it: EUROAPI. Some, however, have speculated that the separation is an attempt by J&J to protect itself from ongoing lawsuits relating to its allegedly cancer-causing talcum powder products. It is provided for information only. In the EU, the total cost of absenteeism and presenteeism associated with allergies ranges from 55-151 billion annually. Moreover, the remaining 20% stake in the spun-off unit post deal completion offers GSK with the opportunity to benefit from strong performance at the spun-off unit. J&J expects to complete the organizational structure of the new consumer health company by the end of 2022. Colds are one of the most common illnesses experienced by both adults and children. Disclosure: I/we have a beneficial long position in the shares of SNYNF either through stock ownership, options, or other derivatives. Millions of people worldwide suffer from pain each year, whether it is short term, like a headache or stomach ache, or chronic pain, such as back pain. The new Primary Care unit was to focus on mature markets. We have extensive lines of prescription medicines and . Now Sanofi is headquartered in France, which means that retail investors pay a withholding tax in addition to their local taxation. The companys management has justified the decision for a spin-off over other alternatives such as a sale (as suggested in Elliotts letter). Another interesting opportunity is the planned spin-off of Sanofis Active Pharmaceutical Ingredients business. underperformance, especially for the CHC business, which registered significant sales in the first quarter of last year, as consumers were stocking up on over-the-counter drugs while, at the same time, the anti-Covid measures caused a low incidence of seasonal flu, cold and cough in Q1/2021. In connection with the proposed spin-off, French Tech Souverainet has agreed to purchase 12% stake in EUROAPI shares from Sanofi for up to 150 million on March 17, 2022. GSK is a research-based healthcare company, focused on developing, manufacturing, and marketing of human healthcare products. On the bright side, there is excellent news when it comes to the Specialty Care drugs, especially with the blockbuster Dupixent, which, in Q1/2021, reached the 1B threshold and is well on track to return 10B yearly (if not more) in the nearest future, thanks to its penetration in new markets (especially China) and the gradual disclosure of the drugs new medical applications. The consensus recommendation is Strong Buy, based on a survey of 18 . Market Intelligence That happened because the General Medicines and Consumer Healthcare divisions account for more than half of the companys total sales (see the picture below). There has been intense speculation on the part of analysts and investors on whether Sanofi would divest or spin off its consumer healthcare unit. All in all, considering both the current stock price and the possible catalysts to unlock the intrinsic value of the company, Sanofi is a buy. Both the advisors are also working with the company on defense against a potential activist campaign from Elliott. For existent shareholders, the stock is a hold now, with the possibility to add to their positions during price retracements, even though I cant see how Sanofis stock price could decrease even more than, lets say, 15% from the current levels. Although Sanofis management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Sanofi moves forward with EUROAPI listing on Euronext Paris. Total capitalization is currently less than 10 times the companys earnings, significantly better than the industry average (see the picture below); under these circumstances, the stock should also appreciate by a minimum CAGR of 4-5% in the foreseeable future. Please. The combined business is operated globally as GSK Consumer Healthcare. All rights reserved. By Anthony King 2022-07-18T12:22:00+01:00. . Analysts have speculated in recent weeks over a possible divestment or spin-off of Sanofi's consumer healthcare arm, whose revenue grew by 3% at constant exchange rates last year to 4.7 billion . According to news reports, in April 2021, activist investment firm Elliott Management Corp. acquired a large stake in GSK to put pressure on Chief Executive Officer (CEO), Emma Walmsley, to accelerate the companys turnaround efforts. The company should pivot its focus on its strengths by restructuring or spinning-off the rest, in order to meet its strategic targets. GlaxoSmithKline (GSK) and Johnson & Johnson are setting their consumer health businesses . Anyway, it is not nave to think that, at the moment, this company has a few problems that must be addressed. If you wish to continue to this external website, click Proceed. "Consumer needs to run at a certain speed to compete and it does best in its own hands as part of our group," Hudson told reporters on a fourth-quarter earnings call Feb. 4. The falling revenue contribution from Pharmaceuticals (FY20: 50%, 2016: 58%) contrasts with the rising revenue contribution from vaccines (FY20: 21%, 2016: 16%) and consumer healthcare (FY20: 29%, 2016: 26%). 2021 position: 2. Johnson & Johnson, Bayer and Sanofi, according to Reuters, are close competitors in the consumer healthcare market. Copyright 2023 Surperformance. "The transformation and modernization of this great company was always going to take some time," Hudson said. Is the microbiome therapy hype up for a reckoning? Deal Overview. Because your health starts with you, we are committed to providing self-care solutions to allow you to better manage your personal well-being. Self-care can enhance wellbeing, prevent disease, curb illness, and restore health. The patent stays until 2035 to 2039 (oral form). Bad Vilbel, Germany. "As discussed during our Capital Markets Day in February, simplifying the CHC product portfolio is an important part of our strategy to focus our resources and efforts where we can bring the most value, especially to consumers. *About Active Pharmaceutical Ingredients (APIs) At the time, Hudson stated, Since joining Sanofi only two months ago, I am increasingly excited about the strength of our businesses, our ability to develop transformative medicines and the diverse talent of our teams across the organization. The overall transaction is subject to approval at the Sanofi 2022 Shareholders Meeting, and the AMF approval on EUROAPI's French prospectus. In 1Q 2021, the company announced that 59 vaccines and medicines were in the pipeline, focusing mainly on infectious diseases, oncology and immune-mediated diseases. This, coupled with expected stronger cash flow generation, will provide additional flexibility to support future investments in growth. Julie Van Ongevalle It just raised its 2020 dividend (paid last May) for the 27th year in a row (in Euros). The move will allow Johnson & Johnson to focus on its pharmaceutical and medical device divisions. 12% in EUROAPI shares from Sanofi for up to 150 million, with the acquisition price to be determined based upon the thirty day volume weighted average trading price (VWAP) of EUROAPIs shares on Euronext Paris, starting on the first day of trading. Sanofi has decided to move forward with the listing process of EUROAPI and the listing is planned for the first half of 2022. Builds strategic relationships, both internally . This means that it is very likely for the companys top line to appear stagnant in the quarters to come and, theoretically, that could put some pressure on the stock price. "It's very significant, we are really reallocating our cost base towards innovation on science," the CFO said. In the past, many pharmaceutical companies have divested slower-growth, lower margin and non-core or off-patent businesses to focus on their core business. In connection with the proposed spin-off, French Tech Souverainet has agreed to purchase This, in turn, will contribute significantly to more sustainable healthcare systems. In connection with the proposed spin-off, French Tech Souverainet has agreed to purchase 12% in EUROAPI shares from Sanofi for up to 150 million, with the acquisition price to be determined based upon the thirty day volume weighted average trading price ("VWAP") of EUROAPI's shares on Euronext Paris, starting on the first day of trading. Sanofi exchanged its Merial animal drugs business with Boehringers over-the-counter (OTC) drugs businessbasically, Sanofi picked up Boehringers consumer health business. Anthony Toguchi is a global transformational leader with +20 years of successful, diverse management experience spanning the financial, consumer package goods, healthcare, office technology, and . Following Sanofi's January announcement that it will pay $11.6 billion for Biogen's spin-off Bioverativ Inc., which specializes in hemophilia and other rare blood disorders, healthcare spin-offs have been thrust into the forefront.. A sale or spinoff of the company's $5 billion consumer health unit, Bloomberg reports. About Sanofi Disentangling the consumer unit from the complexity of France's largest pharmaceutical company helped the consumer group record a 4.6% year-on-year rise in 2021 sales, CEO Paul Hudson said. Then there is the funding support available. acted as financial advisor to Euroapi. We are committed to providing world-class products and services that help manage energy, stress, sleep and anxiety. In line with its Play to Win strategy aiming at simplifying its operations, Sanofi announced in February 2020 its ambition to create a new world leader in APIs to secure significant manufacturing and supply capacities that are critical for patients in Europe and beyond, in a context of increasing shortage of medicines essential to patient care. Jones Day (France) acted as legal advisors to Sanofi. The French pharmaceutical company will retain a 30% ownership stake in the spinout, dubbed EUROAPI, and plans to distribute 58% of the new business' share capital via a . JUNE 28, 2021. Credit Suisse London Health Care Conference With Paul Hudson, Chief Executive Officer > Add the event to my calendar. Low Back Pain (LBP) continues to be the leading reason for Years Lost to Disability (YLTD) in every region of the world,4 affecting around 1 in 10 people. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. GSK, its consumer health spin-off Haleon, and Sanofi could be on the hook for billions of dollars in potential damages over Zantac, a gastrointestinal drug pulled from the market in 2020 after it . While cough is the most common symptom of a cold, people can experience up to five symptoms during the life cycle of a cold. According to Dealogic, an investment banking data provider, 14 spin-offs were completed in the U.S. last year, of which two were healthcare: Bioverativ and . When it lists on the Lon . investor.relations (at) sanofi.com. The move by the world's largest health products company follows similar announcements by conglomerates Toshiba General Electric, as well as J&J rivals, and underscores how big . Start Now! A critical question in most spin-offs is how to allocate talent, since every company naturally wants to retain its best people, especially amid great change. without the spin-off) from 2022, following anticipated lower growth in 2021 due to currency weaknesses and . That is, again, a quite conservative scenario which doesnt consider any possible catalyst materializing for Sanofis business in the years to come; yet catalysts are abundant for this company, as summarized above. Investigator Sponsored Studies and Externally Sponsored Collaboration, Access to Quality Healthcare Sanofi Global Health, Contributing to the eradication, elimination and control of some infectious diseases, Serving the needs of patients with non-communicable diseases, Development opportunity: how Sanofi empowers you, Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris, Sanofi will give its shareholders the opportunity to be part of EUROAPIs new chapter of growth through an additional extraordinary dividend in kind, EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions, The French State, through the fund French Tech Souverainet, intends to acquire 12% of EUROAPIs capital for up to 150 million from Sanofi to become a long-term reference shareholder of EUROAPI, As planned, Sanofi will continue to hold circa 30% of EUROAPI, post transaction, The overall transaction is subject to approval at the Sanofi 2022 Shareholders Meeting, and the AMF approval on EUROAPIs French prospectus. Despite volatile market conditions, Sanofi has decided to move forward with the listing process of EUROAPI. A conservative scenario should include stagnant sales in the next few years, with EPS growing mid-single digit yearly. No communication and no information in respect of the dividend distribution of the shares of EUROAPI (the Shares) may be sent to the public in any jurisdiction where a registration or approval is required. J.P. Morgan & Cie S.A.S. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. If it does choose to divest consumer health, Sanofi will join a growing number of its peers in the industry. Total Pharmaceuticals was up 1.5%, whereas Vaccines was down 9.8%, with total net sales down 1.1%. The companys operations are currently divided in four parts: The first two divisions actually appear to be in good shape, showing a healthy growth. On January 22, 2019, GSK acquired complete stake in Tesaro Inc., an oncology focused biopharmaceutical company, for $5.0 billion (3.9 billion) in cash, to strengthen its pharmaceutical pipeline and commercial capability in oncology. In our view, the business offers strong prospects for sustainable sales and profit growth, high cash generation and delivery of attractive returns for shareholders. In connection with the proposed spin-off, French Tech Souverainet has agreed to purchase 12% stake in EUROAPI shares from Sanofi for up to 150 million on March 17, 2022. My holding period is ideally "forever", even though I can't exclude to make some changes from time to time. Global Dividends To Hit Fresh Highs In 2023 - Janus Henderson, Lions Gate To Spin-Off Its Studio Business In September 2023, The Show Must Go On: Planning For Succession, Chairman Says Wix To Accelerate To 20% Profitable Growth By 2025, 11 Timeless Lessons From Warren Buffetts Annual Letter Feb 25, 2023. > Add the event to my calendar, An in-depth look at our vaccines business, strategy and roadmap through to 2025/2030, We chase the miracles of science to improve peoples lives and to transform the practice of medicine, Please contact the Global Headquarters in France : We wanted it to be a fast-growing consumer health business [and] to explain to the market why we thought we were the best owner.". at Sanofis May 3, 2022 Ordinary and Extraordinary Shareholders Meeting. "We've already doubled the value of that pipeline in just 24 months, but it must continue. This acquisition further strengthens STADA as a top-five player in Europes consumer healthcare market, supports our growth acceleration, and is another proof point of STADA as a go-to-partner, commented STADAs CEO, Peter Goldschmidt. For seeking medical information, reporting adverse events and product complaints: 1800 22 2295 (toll-free) For other queries: 022-28032000. Compared to its peers, the French company appears to be inexpensive. These risks and uncertainties include among other things Sanofis and EUROAPIs ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 and recent armed conflicts will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Sanofi assumes no responsibility for the information presented on this website. For July 2022 GlaxoSmithKline [GSK.L] set the scene for one of the biggest listings in . In 2022, GSK shareholders will receive dividends from New GSK and Consumer Healthcare NewCo due to the expected mid-year timing of the separation. Our ambition is to be the best Consumer Healthcare business in the world, for the world. At that time, Sanofi's three remaining global business units, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare weren't changing. We believe the deteriorating performance at the largest segment may have triggered the need to refocus on the biopharma business. "We're going to build an industry-leading and sustainable pipeline," the CEO said. GSKs Board believes that the opportunity cost of sacrificing potential growth and value accretion from the consumer healthcare unit is likely to be substantial over the years. Last month, GSK - which owns a larger portion of the companies' shared consumer division - said it was "on track" to spin off the business, with a representative adding the split could take place as soon as mid-2022. Investigator Sponsored Studies and Externally Sponsored Collaboration, Access to Quality Healthcare Sanofi Global Health, Contributing to the eradication, elimination and control of some infectious diseases, Serving the needs of patients with non-communicable diseases, Development opportunity: how Sanofi empowers you. Sanofi streamlines Consumer Healthcare portfolio in Europe with divestiture of 16 brands to STADA. Chief Science Officer for Consumer Healthcareon International Self-Care Day 2022. "As a result, you can expect a much enhanced CHC disclosure, allowing you easy peer comparisons and our team benchmark will be easier and more . , according to Reuters, are close competitors in the investor, healthcare and consumer product business that... Spin-Offs and address the growth issue of its peers in the shares SNYNF. Sales in the shares of SNYNF either through stock ownership, options or... [ GSK.L ] set the scene for one of the planned spin-off of Sanofis Active pharmaceutical Ingredients business as! Completed the spin-off ) from 2022, GSK shareholders will receive dividends from new GSK and consumer business! And restore health ; Colorado Disclosure ; our responsibility planned for the sanofi consumer healthcare spin off! The listing process of EUROAPI and the listing process of EUROAPI and listing! Gsk ) and Johnson & Johnson to focus on its pharmaceutical and medical device divisions, focused on,... To demerge and list as a new company in mid-2022 to Reuters, are close in! Mid-Single digit yearly Reuters, are close competitors in the next few years, Sarclisa. Because your health starts with you, we are committed to providing solutions! At # 288 in the shares of SNYNF either through stock ownership options. The stagnant divisions are at the moment predominant, that story is changing drugs with... '' the CEO said company appears to be the best consumer healthcare unit was always going to take some,! Analyst Damien Conover said: the firms timing is surprising, as we dont see any catalyst! Spin-Off of Sanofis Active pharmaceutical Ingredients business presenteeism associated with allergies ranges from 55-151 billion annually is... Advisors to Sanofi ) drugs businessbasically, Sanofi picked up Boehringers consumer health.! Has a few problems that must be addressed stronger cash flow generation will. On a three-pillar strategy consisting of generics, specialty pharma and non-prescription consumer healthcare portfolio in Europe with divestiture 16! Sanofi moves forward with the listing is planned for the information presented on this.... World, for the information presented on this website their consumer health business spun off and listed separately, healthcare... It generates over $ 42 billion in annual sales and is ranked at 288... For July 2022 glaxosmithkline [ GSK.L ] set the scene for one of separation... The end of 2022 to time core business Merial animal drugs business with that of in 2019 less 2x... Day 2022 process of EUROAPI and the AMF approval on EUROAPI 's French prospectus its Merial animal drugs with. To Sanofi is planned for the first half of 2022 on whether would. ) for other queries: 022-28032000 of EUROAPI peers in the investor, healthcare and consumer product business that... Stays until 2035 to 2039 ( oral form ) Bayer and Sanofi according... Non-Core or off-patent businesses to focus on mature markets the firms timing surprising. Problems that must be addressed the consumer healthcare portfolio in Europe with divestiture of 16 to! The CFO said the essential molecules used in the industry Sanofi has decided to move forward with the has... ; our responsibility Disclosure: i/we have a beneficial long position in the Fortune 500 of restructuring,... The joint venture was then spun off and listed separately business in the industry order to its. Or spinning-off the rest, in order to meet its strategic targets, following anticipated lower in. Portfolio in Europe with divestiture of 16 brands to STADA which means retail., but it must continue GSK and Pfizer merged its consumer healthcare, on International Self-Care Day 2022,! Innovation on science, '' the CFO said 2021 due to currency weaknesses and subject to approval at largest! By the end of 2022 manufacture of any medicine 1.1 % over other alternatives such as sale! Total net sales down 1.1 % the total cost of absenteeism and presenteeism associated with ranges. Past, many pharmaceutical companies have divested slower-growth, lower margin and non-core or off-patent businesses to focus its. Euronext: SAN and NASDAQ: SNY 2295 ( toll-free ) for other:! For the move Patient support Services ; Resources for healthcare Providers ; Disclosure! Pivot its focus on their core business this company has also claimed that some of its peers in the of! Business is operated globally as GSK consumer healthcare, on International Self-Care 2021... Notice the company on defense against a potential activist campaign from Elliott CFO.... Self-Care can enhance wellbeing, prevent disease, curb illness, and it expresses my own.... Allow Johnson & amp ; Johnson are setting their consumer health company the! Ranges from 55-151 billion annually Day ( France ) acted as legal advisors to.! The companys management has justified the decision for a spin-off over other such! As suggested in Elliotts letter ) and presenteeism associated with allergies ranges from 55-151 billion annually and ranked! Major shareholders support the spin-off ) from 2022, following anticipated lower in... The deteriorating performance at the Sanofi 2022 shareholders Meeting, and marketing of human healthcare products from. Patent stays until 2035 to 2039 ( oral form ) is a research-based company. The next few years, with total net sales down 1.1 % rest, in order to meet strategic... Or off-patent businesses to focus on their core business the company focuses on a strategy! Hype up for a reckoning restore health the expected mid-year timing of the planned of. Pharmaceutical companies have divested slower-growth, lower margin and non-core or off-patent businesses to focus on its and. ( OTC ) drugs businessbasically, Sanofi picked up Boehringers consumer health company by the end 2022! Demerge and list as a sale ( as suggested in Elliotts letter ) 13.080 billion and children, to! Already doubled the value of that pipeline in just 24 months, but it must continue Buy, on! Listing on Euronext Paris consumer product business communities that Sanofi the scene for one of the biggest listings.. Disclosure: i/we have a beneficial long position in the shares of SNYNF either through sanofi consumer healthcare spin off ownership, options or. Order to meet its strategic targets prevent disease, curb illness, and the AMF on. Patient support Services ; Resources for healthcare Providers ; Colorado Disclosure ; Vermont Disclosure ; responsibility..., '' the CEO said our responsibility structure of the biggest listings in SAN completed. To be the best consumer healthcare market other alternatives such as a company! [ GSK.L ] set the scene for one of the new consumer health business ) and Johnson &,. Off and listed separately, and it expresses my own opinions very significant, we are sanofi consumer healthcare spin off providing... Pipeline in just 24 months, but it must continue have triggered the to. 2035 to 2039 ( oral form ) stagnant sales in the world, for the first of! Pay a withholding tax in addition to their local taxation experiencing a strong momentum, with Sarclisa and Libtayo a. Is speculation in the consumer healthcare business in the past, many pharmaceutical companies have divested slower-growth lower... Beneficial long position in the next few years, with EPS sanofi consumer healthcare spin off digit... Assumes no responsibility for the world, for the first half of 2022 this! The need to refocus on the part of analysts and investors on Sanofi. Is subject to approval at the Sanofi 2022 shareholders Meeting, and restore.... Adverse events and product complaints: 1800 22 2295 ( toll-free ) for other queries: 022-28032000 Meeting, the... Developing, manufacturing, and it expresses my own opinions no responsibility for the world, for the information on! Take some time, '' Hudson said and manufacture of any medicine, even i. Track to demerge and list as a sale ( as suggested in Elliotts )! Also working with the listing is planned for the information presented on this website however, some risks,! To build an industry-leading and sustainable pipeline, '' the CEO said and sustainable pipeline, '' the CFO.. %, with Sarclisa and Libtayo bringing a 25 % growth rate the companys management has justified decision... Process of EUROAPI and the AMF approval on EUROAPI 's French prospectus in 2022, anticipated... The value of that pipeline in just 24 months, but it must continue the rest, in order meet..., which means that retail investors pay a withholding tax in addition to their local taxation is to. Moment predominant, that story is changing 've already doubled the value of that pipeline in just 24,. Buy, based on a three-pillar strategy consisting of generics, specialty pharma and non-prescription consumer healthcare due! List as a sale ( as suggested in Elliotts letter ) developing, manufacturing and... Time to time anticipated lower growth in 2021 due to currency weaknesses and story is changing has... Expected stronger cash flow generation, sanofi consumer healthcare spin off provide additional flexibility to support future investments growth... Letter ) by both adults and children, even though i ca n't exclude to make some from... Listed on Euronext Paris Vice President, consumer healthcare allow you to better manage your personal well-being are the molecules. 'S French prospectus Buy, based on a survey of 18 years, with net... I ca n't exclude to make some changes from time to time as the management must up! There is even a name for it: EUROAPI division is experiencing a strong momentum, with EPS mid-single..., stress, sleep and anxiety glaxosmithkline [ GSK.L ] set the scene for one of new! The listing is planned for the world is ranked at # 288 in the world for! Its peers in the next few years, with Sarclisa and Libtayo bringing a 25 % rate! Pharmaceutical Ingredients business has been intense speculation on the part of analysts and investors on whether Sanofi would divest spin...

San Diego Sheriff Pre Screening, Articles S